Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by TrueNorth911on Dec 08, 2018 6:34pm
88 Views
Post# 29087833

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DMA On Watch Territory

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DMA On Watch TerritoryUuggh....not what we wanted, but I assume they sold all the shares in the IPO and thus are in a much better cash position.... $16M + $3-$4M they had on hand as per last filing vs. burn rate I calculate is $20M.  They should get the $4.5M scheduled payment for Ahon deal FDA approval soon I would think... so sitting on at least $25M cash.

This puts them on a solid footing to complete a series of trials through end of phase 2 I would guess?....   

So corporately and financially they are in a significantly position than before the IPO. If you like the story then, you should LOVE this story now.

So... let's get some NEWS out there!!!!!!! and support the stock and shareholders. There must be a ton of stuff to report.... and I think they are hand-cuffed until the IPO deal closes, which is next week I believe?

In the meantime the naysayers are having their day in the sun, but someone (me included) were smart enough to pickup shares at end of day Friday!!!

I think much better days are ahead, and picture will improve significantly.

This story is FAR, FAR, FAR from what others portray it to be. Sky is not falling folks. Nothing has changed scientifically (except further progess on trials), and they are now well funded for completion of said trials. Hello.... How is this bad?

Stock's go up and down like my under-wear...yep, you need a strong stomach for this to weather the gyrations.... and yeah I lost a little sleep last night as I'm sitting on 300,000 shares folks!

Also... don't forget that the markets overall are selling and bio-tech in a tailspin. BAD TIMING is all this is. Tax-Loss selling is going on as well, multiple factors at play here. 

So...what am I doing about it? I'm buying as much as I can get at these levels.

Bullboard Posts